5 Alternate Health, Inc. | Health Services and Technology

Latest News

Find Out What's New at Alternate Health.

ALTERNATE HEALTH CORP. ANNOUNCE STRATEGIC CHANGE TO ITS GROWING TESTING LABORATORY STRUCTURE

Toronto, ON July 3, 2017 - Alternate Health Corp (CSE:AHG) (OTC:AHGIF) today announced strategic changes in the operational structure of its wholly-owned clinical laboratory, Alternate Health Laboratory, Inc. ("AHL").  These changes will maximize profitability while also positioning AHL to service a potentially larger base then currently available.

AHL will be transitioning from a reference laboratory servicing hospital clients to a full-service clinical laboratory providing toxicology, blood, and pharmacogenetics testing on samples sent directly to AHL by physicians and other healthcare providers.  We believe this change in our business model will better position AHL for sustainable growth in a rapidly changing healthcare environment.

AHL has applied to become a participating provider with Medicare and will apply to other federal insurance carriers and commercial carriers to provide services to beneficiaries covered under their insurance plans.  By positioning our laboratory to bill directly from the payers, we eliminate massive third-party expenses and increase our revenue per sample. We are actively developing our physician referral base for federal and commercial samples.

We anticipate the transition to a full-service laboratory will take several months and may cause a decrease in AHL revenue during the third quarter, but we are embracing this change and making the necessary adjustments to move us forward in a more efficient and profitable manner.  We believe revenue will increase during the fourth quarter and continue as a larger, more secure source of revenue in the future.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:

Nancy Goertzen, CPIR - 1.604.512.7122

Byron Striloff - 1.604.657.8400


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCES APPOINTMENT OF J. BERNARD RICE TO THE BOARD OF DIRECTORS

Toronto, ON June 30, 2017 - Alternate Health Corp (CSE:AHG) (OTC:AHGIF) is pleased to announce that J. Bernard Rice, has joined the Board of Directors of Alternate Health, a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and service delivery.

Mr. Rice is recognized as one of the world’s leading experts in Information Technology. Mr. Rice has a wealth of enterprise business, experience and significant senior level relationships that are indispensable in developing many strategic partnerships. His Partner, General Wesley Clark and Mr. Rice are currently driving in a portfolio of companies with leadership capabilities in Cybersecurity, Green Energy, Medical technologies, Education and Real estate.

Mr. Rice began his career with IBM in sales and held various sales leadership positions until 1983 when he entered IBM's finance fraternity. Mr. Rice's work in business case structure and portfolio analysis led him to a role as IBM's Finance Director for Application Software in 1985. He was promoted several times such that by 1989 he was appointed Director of Finance, Planning and Administration for IBM's Southern Area. In that role, Mr. Rice was responsible for the staff functions of a $3 billion business and he was instrumental in positioning IBM's Southeast Region as the leader in billable services.

 

Mr. Rice became Chief Financial Officer and General Partner for the IBM Venture Capital Group in 1993 and then Vice President of Business development for IBM's Consumer Division in 1998. There he managed projects like IBM's partnership with Berkshire Hathaway and Hallmark for the development of its breakthrough on-line research and learning platforms.

Mr. Rice also served as Chief Executive Officer of Edmark Inc., the IBM subsidiary that developed innovative educational software for children. In 2000 Mr. Rice orchestrated the spin-off of IBM's education content assets into Riverdeep Inc and was instrumental in Riverdeep becoming the fastest growing educational software company in the nation. Today, Riverdeep has educational products in some 45,000 schools in over 20 countries.

Mr. Rice holds a B.A. from St. Anselm College (Manchester, New Hampshire) and a Masters in Business Administration in Marketing from Georgia State University. Mr. Rice also attended the IBM Presidents Program (a special Executive MBA program) at Harvard University.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Investor Relations Contact:

Nancy Goertzen, CPIR - 1.604.512.7122

Byron Striloff - 1.604.657.8400


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH'S CANACARD CONTROLLED-SUBSTANCE MANAGEMENT SYSTEM TO LAUNCH IN ALL OF NATIONAL ACCESS CANNABIS' CLINICS ACROSS CANADA

TORONTO, June 14, 2017 - Alternate Health Corp (CSE:AHG) (OTC:AHGIF), an international medical cannabis company, announced today that the company has reached an agreement to launch its CanaCard Patient Management System in all of National Access Cannabis (NAC) clinics across Canada. Alternate Health uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices.

National Access Cannabis operates ten clinics across Canada, with a specific focus on connecting patients with clear information on the legal treatment options available. In recognition of NAC's leadership in Canadian medical cannabis, Alternate Health has made investments of close to $1,000,000 in the company. Alternate Health believes that this agreement creates a base for further expansion in the Canadian market, including the company's cannabinoid research and delivery systems.

“Alternate Health is taking a step forward in consolidating our leadership position in medical cannabis technology,” says Dr. Jamison Feramisco, CEO of Alternate Health. “National Access Cannabis is a Canadian pioneer in medical marijuana and we are excited to see our technology help NAC benefit patients and generate revenue in a key area of both our businesses.”

The CanaCard Patient Management System is a cloud-based platform that manages the end-to-end transactions involved with providing safe access to medical cannabis for patients across Canada. The database connects patients, certified doctors and licensed producers with a complete set of patient management tools. We ensure the secure storage of personal data, account balances, transactional volume and research data.

Alternate Health will install the system in each of National Access Cannabis' ten clinics across Canada and any new NAC clinics will operate with CanaCard in the future. Revenues will be generated for both NAC and Alternate Health from transaction fees charged on sales between patients and licensed producers of medical marijuana, compliant with Health Canada's rules and guidelines for medical cannabis in Canada.


About National Access Cannabis

National Access Cannabis operates in various cities across Canada and assists patients to improve their quality of life. Our Cannabis consultants guide patients through the process of obtaining the required legal documents to possess Medicinal Cannabis. We also connect patients with a suitable legal Licensed Producer approved by Health Canada. Every patient has access to extensive education and resources to ensure they are confident using their medication, and we also provide them with a convenient Medical Cannabis ID card.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Contact

Mike English, CFO

972.378.3793


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH COMMENTS ON MARKETING ACTIVITIES

DALLAS, TX, June 8, 2017 - Alternate Health Corp ("Alternate Health" or the "Company") (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, commenced trading on its principal trading market, the Canadian Securities Exchange ("CSE") on January 24, 2017, and began quotation in the United States on the OTCQB on March 7, 2017

Since becoming a public company in January 2017, the Company has engaged third party providers (Finsbury, CFN Media, Stockhouse, Investing Media Solutions, Money Channel, Planet Microcap, See Thru Equity and Canada Newswire) to provide public relations, marketing or other related services.  Recently, the Company engaged an advertising and media firm to assist with a managed public awareness campaign, through paid third party agents and newsletter distributors.

On June 6, 2017, the Company received notice from the OTC Markets about promotional activities in relation to the Company and its common shares, including certain promotional newsletter emails.  The Company had not reviewed or seen these newsletters prior to publication and was not aware of the promotional nature of the materials.  Neither the Company nor its officers, directors, and to the best of its knowledge, its controlling shareholders have directly, or indirectly, authorized or been involved in any way with the creation of the promotional materials.

The Company has determined that certain statements included in these newsletters related to the Company and its business may be misleading and/or incomplete and readers should not place undue reliance on these newsletters.  The Company encourages investors to review its filings and disclosures made with Canadian securities regulators, available at www.sedar.com and as posted on the filings and disclosure page for AHGIF on the OTC Markets website at www.otcmarkets.com.

Since becoming a public company on January 19, 2017, the Company has completed two private placements of common shares. The first private placement of 2,914,354 common shares, priced at CAD$1.50, closed on January 20, 2017, with a statutory hold period that expired on May 21, 2017. The second private placement of 2,328,940 common shares, priced at CAD$3.25, closed on March 6, 2017, with a statutory hold period that expires on July 7, 2017.

Since becoming a public company, daily trading volumes have been minimal with volume increasing that the Company attributes to continued advancement of Alternate Health's business, recent earnings news releases and the expiry of the statutory hold period on May 21, 2017 of 2,914,354 common shares.

As disclosed in the Company's news release of April 17, 2017, Alternate Health granted 580,000 incentive stock options to directors, officers and consultants of the Company at an exercise price of CAD$4.00 per common share, and granted an aggregate of 867,544 warrants to officers of the Company at an exercise price of CAD$3.91 per common share.  An officer of the Company acquired 13,333 common shares on May 23, 2017, in a private purchase and sale transaction. In accordance with the rules and policies of the CSE, the Company has not issued convertible securities (warrants or options) below current market price.


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Contact

Mike English, CFO

972.378.3793


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH – THE FIRST CANNABIS COMPANY TO REPORT ADJUSTED EBITDA IN INITIAL FIRST QUARTER

DALLAS, TX, June 7, 2017 - Dr. Jamison Feramisco — CEO of Alternate Health Corp (CSE:AHG) (OTC:AHGIF), an international medical cannabis company that uses best-in-class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices — today congratulated staff, management and investors on reaching the positive cash flow milestone in the Company's first quarter of operation..

"The pace of growth in this company is very promising and I am truly impressed at how far we all have come in less than three months of operations," says Dr. Feramisco. "We are proud to be a profitable medical cannabis company, building shareholder value on real revenues and strategic investments – not just speculation. We are eager to demonstrate continued growth for the rest of 2017 and beyond."

Alternate Health is a fully integrated medical cannabis company, with operations divided among three key business pillars: laboratory services; medical software and regulatory compliance technology, cannabinoid therapy research education; production and delivery systems. In the first quarter, the majority of revenue came from Alternate Health's clinical laboratory testing, through its subsidiary Alternate Health Labs.

The Company generated $3.87 million in revenue in Q1, with operating expenses totalling $5.04 million. A considerable portion of these expenses were non-recurring, share-based sales incentives targeted at its rapidly growing laboratory business. To better reflect the financial results of the Company in its Q1 earnings release, Alternate Health reported Non IFRS measures including Adjusted (normalized) Net Income of $1.1 million or $0.03 per share and Non IFRS Adjusted EBITDA of $1.4 million as defined in its May 30th press release.

"Our success this quarter proves there's a high demand for our services and that we have the commitment and capability to meet that demand," says Dr. Feramisco. "We expect our software and education businesses to begin generating revenues next quarter, with our cannabinoid research and delivery system business following up in the third and fourth quarters."


About Alternate Health Corp.

Alternate Health Corp. (CSE:AHG, OTCQB:AHGIF) is an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices. The company is strategically positioned in all facets of the medical cannabis value chain through the innovative integration of proprietary technology and know-how, acquisitions and partnerships, deep direct knowledge of and experience with improving patient outcomes, and management expertise.

Alternate Health is well positioned to reinvest internal operating cash flow in its platform over the long term, creating an attractive investment profile for its shareholders. The company is headquartered in the Dallas-Fort Worth Metroplex with operations in Los Angeles, San Antonio and Toronto.

For more information about Alternate Health Corp., visit www.alternatehealth.ca

Contact

Mike English, CFO

972.378.3793


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH LAUNCHES A CANNABIS/CBD LARGE-SCALE CLINICAL STUDY ON POST-TRAUMATIC STRESS DISORDER (PTSD) FOR VETERANS

Toronto, ON, June 6, 2017 Alternate Health Corp. (CSE:AHG, OTC:AHGIF)), a diverse healthcare company revolutionizing patient care and research through compliance and technology in the emerging medical cannabis industry, is delighted to announce the upcoming launch of a new clinical study on the effects of Cannabidiol (CBD) in the treatment of veterans suffering from Post-Traumatic Stress Disorder (PTSD). Veterans' activist, Wesley Clark Jr., who himself served in the US Military, will lead the study beginning in June 2017.

"Cannabis is the treatment for PTSD," says Wesley Clark Jr., leader of the initiative. "This study will finally demonstrate irrefutable evidence, forcing the FDA to make a change for the better."

Alternate Health will conduct the PTSD study at its newly acquired Neubauer Center in Lauderdale-By-The-Sea, Florida, with the help of veterans suffering the effects of PTSD. The study will research the results of CBD administered through Alternate Health's delivery systems technology, building on the company's research assets. The company expects the results to bolster support and awareness of CBD in the medical community, with possible scientific breakthroughs forming the potential basis of new technology and patents.

Wesley Clark Jr.'s father, General Wesley Clark joined Alternate Health's Board of Directors in April 2017. A retired U.S. Army General and NATO Commander, General Clark shares his son's advocacy for veterans' health, from acute injuries to psychological trauma.

"Throughout my son's career, he has always been a strong proponent of veterans' rights and the anecdotal evidence of the treatment of PTSD with cannabis," says General Wesley Clark Sr. "We both look forward to corroborating this evidence with hard science."

Alternate Health and the Neubaurer Center previously collaborated on the successful Zika Virus Symptom Study, researching the use of CBD in treating patients suffering from the chronic effects of post-viral infection.

"Through this study, Alternate Health has the opportunity for substantial contribution to those who suffer from PTSD. We are honored to provide support for our Veterans and are eager to apply and study what we have learned about CBDs in other fields of medicine toward treating PTSD," says Dr. Jamison Feramisco, CEO Alternate Health.


About Wesley Clark Jr.

Wes was born in Jacksonville, Florida while his dad was in Vietnam. He spent four years in the military himself, and now resides in Los Angeles, California where he works as a screenwriter, and occasionally guest hosts on The Young Turks progressive internet show.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH ANNOUNCES NOTICE OF CHANGE OF AUDITOR

Toronto, ON, June 2, 2017 Alternate Health Corp. (CSE:AHG, OTC:AHGIF)wishes to announce that its Board of Directors have approved a change of the Company's auditors from Scarrow Yurman & Co. Professional Corporation ("Scarrow") to BDO Canada LLP ("BDO").

At the request of the Company, Scarrow has resigned as auditor of the Company effective May 23, 2017. The Audit Committee and the Board of Directors of the Company have appointed BDO as the successor auditor in their place effective May 23, 2017. The Company has sent a Change of Auditor Notice (the "Notice") to each of Scarrow and BDO, and has received a letter from each addressed to the securities commissions in each of British Columbia, Alberta, and Ontario (the "Commissions") stating they agree with the information contained in the Notice. A copy of each letter from Scarrow and BDO addressed to the Commissions will be filed on SEDAR with a copy of the Notice.

There were no disagreements or unresolved issues with Scarrow on any matter of audit scope or procedure, accounting principles or policies, or financial statement disclosure. It is the Company's opinion that there have been no reportable events, (as defined in National Instrument 51-102 (Part 4.11)) between the Company and Scarrow and Scarrow did not have any reservation in their auditors' report for the financial statements for the Company's last two fiscal years or for any period subsequent to the date the most recent audit report was issued and preceding the date hereof.

Alternate Health's CEO, Dr. Jamison Feramisco stated: "I would like to express our sincere gratitude to Scarrow on behalf of the shareholders and the board of directors, and we look forward to working with BDO going forward".


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



Alternate Health Corp. Reports First Quarter 2017 Financial Results.

Company Generates Revenue of $3.9 Million and Adjusted EBITDA of $1.4 Million – (35 Percent) During Its First Quarter as an Operating Public Company

Dallas, Texas(Business Wire), May 30, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF), an international medical cannabis company that uses best in class technology, research, education, production and laboratories to increase the awareness, regulatory compliance, and appropriate usage of cannabinoids in modern medical practices, today announced its results for the first quarter ending March 31, 2017.All dollar references in Canadian dollars unless otherwise noted.

First Quarter 2017 Financial Highlights

  • Revenue of $3.9 million compared to Nil in Q1 of last year
  • Adjusted EBITDA of $1.4 million compared to Nil in Q1 2016
  • Net loss of $0.6 million, up from a loss of $0.1 million in Q1 of last year
  • Working capital of $10.5 million, up from $0.5 million at year end 2016
  • Total assets of $30.9 million, up $28.6 million from year end 2016
  • The company ended the quarter with $11 million in cash on hand and $0.5 million in debt

Revenue for the quarter was driven by strong performance from Alternate Health Labs, a clinical laboratory acquired in January of this year. The net loss of $0.6 million was in part due to $1.6 million of non-recurring, non-cash expense. We raised $11.1 million in new capital during the first quarter and generated $0.2 million cash from operating activities. We also placed $1.0 million in strategic partner investments.

For the first quarter 2017, Net loss per share (Per International Financial Reporting Standards or "IFRS") was $0.02 and non-IFRS fully diluted earnings per share was a positive $0.03. Adjusted net income was $1.1 million compared to negative $0.1 million for the same period last year.

Note – Alternate Health Corp ("the Company") was formed in January 2017 from a reverse take-over of a privately held operating company, Alternate Health Inc. ("AHI"). Per the accounting guidance, the Company's first quarter operating statement ending March 31, 2017 is compared to the first quarter 2016 of AHI. Similarly, the Company's balance sheet at March 31, 2017 is compared to the December 31, 2016 balance sheet for AHI.


Adjusted EBITDA Margin 35.3% - % 35.3 pts

(1) Adjusted earnings before interest, taxes, depreciation and amortization

(2) A reconciliation of IFRS to non-IFRS adjusted results is included in this press release and our Management Discussion and Analysis dated May 30, 2017 and available at www.sedar.com

About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. The Company cautions that the EBITDA and adjusted Net Income figures reported in this new release do not have standardized meaning under IFRS and therefore may not be comparable to similar measures presented by other issuers.


Read Entire Press Release...

Alternate Health Announces Completion of Initial Study to Treat Zika Virus Symptoms with Hemp-Derived Cannabinoid.

TORONTO – May 16, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF), a diverse healthcare company revolutionizing patient care and research through compliance and technology in the emerging medical cannabis industry, announced today the completion of its initial study to demonstrate the effectiveness of cannabinoid in treating chronic post-Zika virus symptoms.

The study, conducted at the Neubauer Hyperbaric Neurologic Center, evaluated the effectiveness of combining treatment with hyperbaric oxygen (HBO) and industrial hemp-derived cannabinoid to alleviate the rare but debilitating chronic post-Zika infection symptoms of pain, fatigue, anxiety, depressive state, and loss of appetite

The Zika virus is a flavivirus transmitted by mosquitos, and over the past 10 years has caused infection in more than 50 countries worldwide. Zika has been declared a pandemic and is considered a Public Health Emergency by the World Health Organization. The Centers for Disease Control and Prevention (CDC) has confirmed there is scientific consensus that Zika causes birth defects, and reports have linked its infection to an infrequent but serious neurological condition, Guillain-Barré Syndrome.

Although acute Zika infection is usually self-limiting, some patients can experience prolonged periods of severe fatigue, joint pain, loss of appetite, anxiety, depressive state, and lethargy after clearance of acute viral symptoms. It is these symptoms in this subset of Zika-infected patients that Alternate Health evaluated in its initial cannabinoid-based, Institutional Review Board (IRB) approved research study.

All 10 patients enrolled in the study demonstrated a significant improvement in their subjective symptoms in less than a month of dual therapy with the Alternate Health Corporation's proprietary hemp-derived sub-lingual dissolvable cannabinoid tablet combined with hyperbaric oxygen treatments.

"The initial results suggesting symptomatic improvement of post-Zika infection-related symptoms by combining cannabidiol – a known anti-oxidant and anti-inflammatory agent – with hyperbaric oxygen is extremely exciting," said Dr. Jamison Feramisco, CEO, Alternate Health. "Although this small study will need to be expanded and reproduced, it demonstrates the vast potential of cannabinoid and medical cannabis therapy to have broader applications for patients suffering from various disease states."

Alternate Health plans to expand its support of clinical trials at the Neubauer Center with the use of its hemp-derived cannabinoid products including sub-lingual dissolvable tablets to treat symptoms of other post-viral infections and conditions including Post-Traumatic Stress Disorder (PTSD) and Chronic Traumatic Encephalopathy (CTE)


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH PROVIDES CLARIFICATION UPDATE ON CONTINUING MEDICAL EDUCATION COURSES

TORONTO – May 15, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF), a leader in complementary medicine and patient-focused healthcare, today announced an update and clarification on the first-ever Continuing Medical Education (CME) course approved for AMA PRA Category 1 Credit(s)TM regarding treatments of Chronic Traumatic Encephalopathy (CTE), including Cannabis.

This course has been created in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the University of Louisville and Alternate Health Corp.

Alternate Health Corp wishes to stress that neither the American Medical Association (AMA) nor the ACCME have in any way approved cannabis or cannabis related products or treatments in conjunction with Alternate Health Corp. education programs or its public announcements. Alternate Health's CME courses are designed to meet the certification requirements of the ACCME but such certification does not comment on or imply any direct endorsements of cannabis products or cannabis treatments by this organizations.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. In leveraging the company's assets in exclusive patents and partnerships, Alternate Health's goal is to be the global authority on the science, manufacturing and delivery methods for cannabidiol (CBD) and other cannabinoids.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



Alternate Health announces first-ever American Medical Association (AMA) approved Cannabis and Chronic Traumatic Encephalopathy (CTE) Treatment for Continuing Medical Education accreditation.

DALLAS, TEXAS – May 11, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) announced today that its Continuing Medical Education (CME) program for doctors on Chronic Traumatic Encephalopathy (CTE) and Cannabis has been approved and accepted by the Accreditation Council for Continuing Medical Education (ACCME) in partnership with the American Medical Association (AMA). Through the course, doctors learn the latest techniques and breakthroughs in CTE research, and fulfill their CME requirements at the same time.

"We are extremely excited to add this CTE protocol to our existing library of medical cannabis accredited courses," says Dr. Jamison Feramisco, CEO of Alternate Health Corp. "Through our partnership with the University of Louisville, we have created an educational series that instructs doctors how to use cannabis as an emerging treatment for CTE and other medical disorders."

In order to demonstrate the quality and comprehensive nature of this program, Alternate Health has included an introductory video (https://vimeo.com/216875569) of the Chronic Traumatic Encephalopathy (CTE) and Cannabis Course, and will commence sales of the online course on our website (www.alternatemedical.com) and at events across the United States and Canada.

CTE is a progressive degenerative disorder found in people who have suffered brain trauma through repeated concussions, micro-concussions or blows to the head. The disorder gained recognition through high-profile cases in athletes, like NFL players or boxers, who have suffered recurrent injuries throughout their careers. Signs of CTE usually begin to show 8-10 years later, with symptoms ranging from dizziness and memory loss to vertigo and dementia.

Launched through Alternate Health's subsidiary, Alternate Medical Media, the CTE and Cannabis course is the first CME of its kind recognized by the AMA. The course builds on Alternate Medical Media's previously AMA-approved course on The Endocannabinoid System and Cannabidiol (CBD) and continues to strengthen the company's research and education assets.

"We will continue to publish high quality educational programs for physicians and those in the cannabis industry who wish to know the science behind the body's endocannabinoid system," says Dr. Feramisco. "Alternate Health's CME courses are set to lead the discussion on how to use cannabis in treating a wide range of ailments."

These CME programs will be available to doctors, scientists and the public online at www.AlternateMedical.com and offer full accreditation and certificate level courses on medical distribution, deployment and the delivery of CBD and THC.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a technology-focused healthcare company, driving innovation in complementary medicine, clinical research and medical cannabis. Based on a portfolio of clinical laboratories, research studies and medical software, Alternate Health invests in research, testing and production for the medicinal and therapeutic use of Cannabidiol (CBD) and other cannabinoids. Leveraging the company's assets in exclusive patents and partnerships, Alternate Health positions itself to be the global authority on the science, manufacturing and administration of medical cannabis.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP REPORTS FULL YEAR 2016 FINANCIAL RESULTS

DALLAS, TEXAS – May 8, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) )), a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry, today announced its results for the full year ending December 31, 2016.

Dr. Jamison Feramisco, CEO of Alternate Health, said: "Our activities in 2016 set the foundation for the company to fully activate its operations in 2017. We successfully completed our share exchange agreement with Alternate Health Inc., which became a wholly-owned subsidiary of the company, and received approval to list our shares on the Canadian Securities Exchange ("CSE") with trading commencing on January 24, 2017. We also began to develop relationships across our businesses that led to agreements which closed in early 2017 including a lab development agreement with Dr. Michael Murphy to establish a 17,000 sq ft toxicology laboratory in San Antonio, Texas. The facility has the capacity to process up to 70,000 urine and blood samples per month and sufficient space to double its processing capacity."

Dr. Feramisco continued: "We've built on our progress in 2016 by announcing numerous developments in Q1 of 2017 that strengthen Alternate Health's financial and business profile. First, we improved the company's liquidity by closing two private placements for net proceeds of $11.3 million and listing our shares on the OTC bulletin board exchange. Second, we expanded our Board of Directors and management team to bring additional clinical corporate expertise in the oversight of Alternate Health's emerging medical operations. Third, we closed eight acquisitions, licenses or strategic investments that strengthen the Alternate Health's position in key markets and provide new growth opportunities. We're excited with our progress year-to-date and looking forward to providing updates on our performance in the coming months."


Full Year 2016 Compared to Full Year 2015:

  • Sales were $0.2 million compared to $0.2 million.
  • Operating expenses were $1.7 million compared to $0.4 million.
  • Net loss was $1.8 million, or $0.06 per diluted share, compared to a net loss of $0.2 million, or $0.01 per diluted share.
  • The 2016 net loss included a one-time charge of $0.7 million for the reverse acquisition transaction of Alternate Health Corp. and listing on the Canadian Securities Exchange.

Liquidity and Capital Resources:

  • The Company concluded the quarter ended December 31, 2016, with $570,003 in cash and cash equivalents as compared to $429,836 as of December 31, 2015. At December 31, 2016, the Company had working capital of $455,397.
  • In the first quarter of 2017, the Company closed two private placements for net proceeds of $11.3 mil. Additionally, share purchase warrants exercised in the first quarter generated proceeds of $627,501. Together these proceeds put the Company in a strong working capital position.
  • The Company has dual-listed its shares on the Canadian Securities Exchange ("CSE") and on the OTC bulletin board ("OTC") to improve the stock's liquidity.
  • Management, directors, and insiders of the Company currently own approximately 30 million common shares (58% of the current shares outstanding) and are committed to building long term shareholder value for the benefit of all its stakeholders.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Graham Buck: Graham.Buck@finsbury.com

Alex Kovtun: Alex.Kovtun@finsbury.com


Cautionary Disclosure Regarding Forward-Looking Statements

Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

This press release may contain certain forward-looking statements within the meaning of applicable Canadian and United States securities laws. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "may," "will," "could," "would," "should," "anticipate," "predict," "potential," "continue," "expect," "intend," "plans," "projects," "believes," "estimates," "confident" and similar expressions are used to identify these forward-looking statements. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. Except as required by law, Alternate Health Corp. undertakes no obligation to update these forward looking statements.


ALTERNATE HEALTH CORP

Consolidated Statements of Loss and Comprehensive Loss

For the years ended December 31, 2016 and 2015



2016

2015


Revenue



License revenue

$ 183,398

$ 167,496

Miscellaneous income

148

59



183,546


167,555

Operating expenses



Advertising and promotion

13,428

-

Amortization

2,465

2,426

Amortization of intangible assets

93,635

73,219

Bank charges and interest

3,129

3,483

Business development

106,539

-

Consulting fees (recovery)

173,057

(8,083)

Interest on longterm liabilities

67,275

22,548

License fee expense

1,248

5,583

Office and general

45,764

26,838

Professional fees

160,233

108,796

Rent

115,757

121,848

Salaries and related benefits

40,170

40,170

Sharebased compensation

818,100

-

Travel

24,394

4,017



1,665,194


400,845


Loss before undernoted items and income taxes


$ (1,481,648)


$ (233,290)


Other expenses



Reverse acquisition transaction cost

107,919

-

Listing expense

594,900

-



702,819


-


Loss before income taxes


(2,184,467)


(233,290)

Income taxes

431,220

-


Net and comprehensive loss


$ (1,753,247)


$ (233,290)


Loss and comprehensive loss (basic and diluted) per share


(0.0564)


(0.0079)


Average weighted number of common shares outstanding (basic and diluted)


31,069,949


29,476,096



ALTERNATE HEALTH TO ACQUIRE FLORIDA-BASED NEUBAUER HYPERBARIC NEUROLOGICAL CENTER FOR ADVANCED CANNABINOID TESTING AND CLINICAL STUDY

PLANO, TEXAS – May 5, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) )), a diverse healthcare company revolutionizing patient care and research in the emerging medical cannabis industry, announced an agreement to acquire Neubauer Hyperbaric Neurological Center (NHNC) in Lauderdale-By-The-Sea, Florida, a pioneer and national leader in neurological disorder research and treatment.

Through this acquisition, Alternate Health will be positioned to be a major player in the Florida healthcare market, which is the third most populous state and holds the largest proportion of elderly residents in America. Alternate Health plans to leverage the decades of research, therapeutics, and expertise of the Neubauer Center to expand novel care delivery models and to perform clinical trials.

"Following Florida's vote last year to legalize medical cannabis, there are countless new opportunities for cannabinoid research and treatment across the state, including the hemp-derived Cannabidiol (CBD) compounds that we are focused on," said Dr. Jamison Feramisco, CEO, Alternate Health Corp. "The Neubauer Center acquisition strengthens our goal to put patients in charge of their healthcare options, while opening up new revenue streams in untapped markets."

Founded in 1972 by world-renowned physician Dr. Richard A. Neubauer, the Neubauer Hyperbaric Neurological Center was South Florida's first Hyperbaric Oxygen Treatment (HBOT) clinic and research facility. For 45 years, the Center has obtained a global reputation as the leader in HBOT research for the treatment of neurological disorders and other illnesses. The late Dr. Neubauer's family continues to operate the clinic.

Alternate Health and the Neubauer Center are currently collaborating on clinical studies researching the use of Cannabidiol compounds in treating patients suffering from chronic fatigue and persistent pain following the Zika virus infection. Concurrent with the acquisition, Alternate Health plans on both continuing the study of CBD and HBOT treatments in patients suffering from chronic post-flavivirus signs and symptoms and also in other fields of neurologic and mental health research.


About the Neubauer Hyperbaric Neurological Center

Having treated patients since 1972, Neubauer Hyperbaric Neurologic Center is a pioneer in the use of HBOT for neurological conditions in the Greater Miami Area. The results of founder Dr. Neubauer's scientific studies (through the Center) have been published in a variety of respected medical journals, including Lancet and the Journal of the American Medical Association.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Graham Buck

Graham.Buck@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



LEADING MEDICAL CANNABIS RESEARCH COMPANY ALTERNATE HEALTH CORP. TO PRESENT AT PLANET MICROCAP SHOWCASE 2017

PLANO, TEXAS – April 25, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) ), a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and research in the emerging medical cannabis industry, will present a business update at the Planet MicroCap Showcase conference in Las Vegas at 9 a.m. PT on Thursday, April 27, 2017.

Stock Options

The Company also wishes to announce that it has granted incentive stock options to certain directors, officers, and/or consultants of the Company for the right to purchase up to an aggregate of 580,000 common shares of the Company, exercisable at the price of CAD$4.00 per share for five years. The effective date of the grant of option is April 14, 2017. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.

Dr. Jamison Feramisco, CEO of Alternate Health, will lead the presentation and also be meeting with investors one-on-one at the conference. Alternate Health is among the top performing medical cannabis companies in the world today. With American Medical Association-approved educational programs, software and patented delivery medical systems, Alternate Health Corp is positioned for rapid growth. To schedule an in-person meeting, contact Robert Kraft, editor-in-chief of StockNewsNow.com, the conference organizer, at 424-227-9018 or rkraft@snnwire.com. Visit www.PlanetMicroCapShowcase.com for more information.

The Planet MicroCap Showcase is a conference that brings together promising companies and the top dealmakers in microcap finance for three days of company presentations, one-on-one meetings, and networking.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Graham Buck

Graham.Buck@finsbury.com


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. ANNOUNCES WARRANTS AND STOCK OPTION GRANTS

PLANO, TEXAS – April 17, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) today announced that it has entered into various employment and management agreements (the 'Agreements') with certain officers of the Company. Pursuant to the terms of the Agreements, the Company will grant an aggregate of 867,544 warrants to purchase AHC shares at a price of USD$2.93 or CAD$3.91 per common share for a period of five years from the date of issuance. The effective date of the grants is April 14, 2017.

Stock Options

The Company also wishes to announce that it has granted incentive stock options to certain directors, officers, and/or consultants of the Company for the right to purchase up to an aggregate of 580,000 common shares of the Company, exercisable at the price of CAD$4.00 per share for five years. The effective date of the grant of option is April 14, 2017. The stock options granted will be in accordance with the Company's Stock Option Plan and will have the required four months hold period legend, pursuant to the Policies of the CSE and regulatory authorities.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

For further information, please contact Jim Griffiths at 416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



GENERAL WESLEY CLARK JOINS ALTERNATE HEALTH CORP. BOARD OF DIRECTORS.

PLANO, TEXAS – April 10, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) today announced that General Wesley K. Clark, former NATO Supreme Allied Commander, has joined the Board of Directors of Alternate Health, a diverse healthcare company that uses its expertise in technology and data analytics to revolutionize patient care and service delivery. General Clark will assist and advocate for the company in its work to develop new treatments for patients suffering from post-traumatic stress disorder (PTSD).

Dr. Jamison Feramisco, CEO of Alternate Health said: "We are honoured that General Clark has joined the Board. As one of our country's most decorated public servants and a champion of the health of our veterans, General Clark will bring critical energy and resources to Alternate Health's work."

General Clark said: "Over my career, I've seen thousands of veterans return home each year with medical issues and ailments ranging from acute injuries to ongoing PTSD. We must explore innovative options for treating these and other debilitating conditions, and Alternate Health is on the frontlines of this effort. I'm looking forward to working with them to address veterans conditions and improve the lives of many Americans and international citizens."

General Clark served a distinguished career in the U.S. Army and rose to a four-star general as NATO's Supreme Allied Commander. Since retiring from the military in 2000, he has served in several capacities in the private sector and has chaired several public and private companies in the energy, banking and business services field. In addition to being a noted author and political commentator, he graduated first in his class at West Point and completed degrees in Philosophy, Politics and Economics at Oxford University as a Rhodes scholar. Among his awards are the Presidential Medal of Freedom, the Silver Star, Purple Heart and honorary knighthoods from the United Kingdom and the Netherlands.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

For further information, please contact Graham Buck
Email: Graham.Buck@finsbury.com Phone: 416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. (CSE:AHG) (OTC: AHGIF) ANNOUNCED BOARD RESTRUCTURING AND APPOINTING A NEW CEO AND CHAIRMAN.

PLANO, TEXAS – April 5, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) today announced that it has named Dr. Jamison Feramisco as CEO (current AHC Director) and Dr. Michael Murphy as Chairman of the Board of Directors. These appointments represent significance in bringing additional clinical corporate expertise in the oversight of Alternate Health's emerging medical operations.

Dr. Feramisco is an M.D.,Ph.D., and is a graduate of the University of Texas at Southwestern Medical School. He is trained in both Internal Medicine and Dermatology and conducted his thesis research in the labs of Nobel Laurates Drs. Michael Brown and Joseph Goldstein MD, earning a Ph.D. degree in Molecular Genetics and Biochemistry. Dr. Feramisco brings Alternate Health a high level f experience and success in transforming corporate growth to profitability, strategic mergers and acquisitions, regulatory oversight and dynamic healthcare innovation across medical technology, digital health, big data analytics, and clinical services.

Dr. Michael Murphy currently manages the Alternate Health Clinical Laboratories and is the majority interest shareholder in Clover Trail LLC, a foundational partner of Alternate Health. Dr. Murphy is a M.D. specializing in Anesthesiology and Interventional Pain Management with a focus on alleviating chronic pain. He holds a very successful track record in acquiring and managing several medical service practices, clinics and Ambulatory Surgery Centers. He has also served on the Boards of various financial institutions. His wealth of experience and knowledge in laboratory operations, management, and regulatory compliance will a serve key function in supporting Alternate Health's business.

Alternate Health would also like to announce the resignation of Bryan Korba as Chairman, CEO and Director. Mr. Korba was hired to transition Alternate Health into a public listing, and to recruit and engage a suitable management team to grow the company.

"We are thrilled with the substantive work that Mr. Korba has done for Alternate Health thus far," said Dr. Jamison Feramisco, CEO. "He has provided a strong foundation by which myself and the Board can further to grow and expand the services of the company. We have requested that Bryan continue his contributions and stay with us as President of Alternate Health."


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

For further information, please contact Jim Griffiths at 416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



ALTERNATE HEALTH CORP. SETTLES DEBT

PLANO, TEXAS – March 17, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the "Company")announces that it has entered into a debt settlement agreement with the holder of a secured promissory note in the amount of USD$1,993,750. The debt was resulting from the Company's purchase of a 20% interest in Clover Trail Capital LLC as announced in the Company's news release of March 8, 2017. The Company has agreed to issue 800,387 common shares at a deemed price of $3.315 per common share to MLM Heritage Trust in consideration of extinguishment of the debt. The shares will have a four month hold period under Canadian securities laws.

Bryan Korba, Alternate Health's CEO indicated, "We are delighted to have reached this agreement because this will eliminate the associated interest expense and free up future cash flows to fund our growth strategy".


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release. Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.



Alternate Health Announces US Listing On the OTC, And The Closing Of An Additional $7.5 Million In Funding

PLANO, TEXAS – March 10, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the "Company"), Alternate Health announced today that it has listed its shares for trading on the OTC bulletin board under the ticker symbol AHGIF, joining other top medical cannabis companies like Canopy Growth Corporation (TSX:WEED.TO) and GW Pharmaceuticals (NASDAQ:GWPH) in the largest cannabis market in the world.

Yesterday, Alternate Health also announced the closing of its recent capitalization of $7,569,055, less a finder's fee of $259,330.50. The company issued 2,238,940 common shares at a price of $3.25 Canadian ($2.50 US). The company currently has an on-hand cash position of over $12 million, all common shares issued under this private placement have a 4-month hold period in accordance with regulators and expiring July 7, 2017. Finders fees will be paid as permitted by the CSE policies and applicable securities laws.

"We are very excited to introduce the Alternate Health companies to American shareholders, as we have tremendous business interests in the US through our labs and technologies, as well as a growing suite of patented pharmaceutical delivery systems for medical cannabis," said Bryan Korba, CEO of Alternate Health Corp. "Our laboratory business is very profitable and that serves to fund development of our software and technology, as well as conducting research and obtaining the approvals necessary for our patented delivery systems."

Alternate Health (https://youtu.be/HX_qGSlIBjA) will continue to leverage its strengths to grow while conducting ongoing clinical studies that demonstrate the effectiveness of our products and our unique, patented medical cannabis delivery systems.

Through ongoing research and testing, Alternate Health will demonstrate its market leading position in this emerging sector of Healthcare.


Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



Alternate Health Corp. Announces Closing of a $7.5M Non-Brokered Private Placement

PLANO, TEXAS – March 9, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the"Company") is pleased to announce that it closed on March 6, 2017, a non-brokered privateplacement with gross proceeds of CAD$7,569,055 less finder's fees of CAD$259,330.50.

The Company issued 2,328,940 common shares at a price of CAD$3.25 (USD$2.50) per share.All common shares issuable under the private placement have a four-month hold period inaccordance with securities laws, expiring on July 7, 2017. Finder's fees will be paid as permittedby CSE policies and applicable securities laws.

Alternate Health Corp. intends to use the proceeds of the private placement for generalworking capital purposes and continued acquisition and investment activities in the growingmedical cannabis industry and as it leverages its expertise in technology to revolutionize patientcare and service delivery.


Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



Alternate Health Acquires Stake in Clover Trail Capital LLC Acquisition Includes Partial Ownership of Sun Clinical Laboratories

PLANO, TEXAS – March 8, 2017 - Alternate Health Corp. (CSE:AHG, OTC:AHGIF) (the "Company"), a diversified healthcare services company that uses its expertise in technology to revolutionize patient care and service delivery, announced today that it has reached an arms-length agreement to acquire a 20 percent interest in Clover Trail Capital LLC ("Clover Trail"), a Texas-based investment company. The acquisition is valued at US $5.5 million.

Clover Trail's investments include a comprehensive laboratory, performing complex lab studies for both toxicology and blood, servicing hospital groups, private insurance groups and large clinics. The acquisition gives Alternate Health Corp. an ownership in Sun Clinical Laboratories LLC, which is 40 percent owned by Clover Trail, and currently refers toxicology and blood samples to the Company's subsidiary Alternate Health Labs, Inc.

Alternate Health Corp. has operations in the United States and Canada. In addition to laboratory services, it is a leader in proprietary software applications for the medical industry. "We are delighted to be joining forces with Clover Trail," said Bryan Korba, Chairman and Chief Executive Officer of Alternate Health. "It is an excellent opportunity for us to grow and increase the effectiveness of Alternate Health Labs, already a leading source of revenue for us and a key part of our strategy to fundamentally advance patient care."

The Company funded the acquisition through an issuance of 4,557,150 common shares, subject to a four-month holding period and an 18 month term note of US$ 1,993,750 payable to one of the sellers. After January 2018, the sellers have an option to put additional ownership of Clover Trail to the Company. Any future sales will be at a price based on a valuation by a mutually agreed independent business valuator.

"This is a winning agreement for both companies," said Dr. Michael Murphy, who indirectly controls Clover Trail Capital and recently completed a Lab Development Agreement with Alternate Health. "Our goal is to make healthcare laboratory services more efficient and costeffective, and with this move we take a major step in that direction."


Contact

Jim Griffiths

Director of Investor Relations

416-607-5757


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



ALTERNATE HEALTH CORP. CLOSES LICENSE TRANSACTION WITH SENTAR PHARMACEUTICALS

VANCOUVER, B.C. – March 3, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company" or AHC) is pleased to announce the finalization and closing of its transaction with EFT Global Holdings, d.b.a Sentar Pharmaceuticals ("Sentar"); on March 2, 2017; an exclusive agreement for non-pharmaceutical sublingual delivery of CBD and THC. The transaction was previously announced in the Company's news release disseminated on January 19, 2017. The Company wishes to note a correction to the January 19, 2017 news release pertaining to the issuance of 2,118,500 common shares in various consulting fees. Pursuant to the stipulation in the agreement, the accurate amount is 2,118,506 common shares in consulting fees.


Under to the terms of the agreement, AHC entered into a 10-year renewable license agreement with Sentar, whereby Sentar has agreed to grant AHC a 10 year worldwide license rights to its patented Sublingual Delivery Systems to administer CBD and THC nutraceuticals in tablet form ("Technology"). Consideration paid to Sentar by AHC for the license consists of 850,000 AHC common shares at a deemed price of $1.00 per share plus a royalty on future sales or profits; and 2,118,506 AHC common shares at a deemed price of $1.00 per share for various consulting fees for services rendered in assistance with obtaining the license, the ongoing development and commercialization of the Technology, and assistance in obtaining regulatory approvals and permits for related products. All parties to the license and consulting agreements are at arm's length to the Company.


The Sentar share issuance totalling 2,968,506 is subject to a four month hold.

About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Bryan Korba

CEO and Chairman

For further information, please contact Thomas F. Bartlett at 1.214.906.0684.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.



ALTERNATE HEALTH CORP. APPOINTS NEW DIRECTORS AND OFFICERS OF THE COMPANY

VANCOUVER, B.C. – February 10, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company") is pleased to announce recent appointments to the Company's Board of Directors and Officers of the Company. The following Directors and Officers have been appointed:


Bryan Korba – Chairman and Chief Executive Officer

Bryan has spent the last 17 years as the Managing Partner of JDIFU Capital, a consulting and private equity investment company he co-founded with his late father and mentor, Robert Korba. The company manages the assets and private equity investments of the Korba Family Investment Office. JDFIU Capital has completed over $100 million in investments in varied industries including healthcare, real estate, software, franchising, hospitality, furniture and financial services. Additionally, Bryan has consulted with many CEOs on mergers and acquisitions, strategic planning, corporate development and company culture and governance. Bryan currently serves on the board of Empower Heroes, a charity he cofounded that services veterans and their families as they re-enter civilian life. Bryan previously served on the boards of 36 Power Equity, Luxe Home, Dallas Challenge and the UNT Venture Fund. Bryan earned a MBA in finance from Texas Christian University and a BBA in economics from the University of North Texas and continues to guest lecture on real estate and entrepreneurial ventures.

Michael English – Chief Financial Officer

Mike English has over 30 years' experience working in diverse industries including data security and encryption software, telecommunications, and heavy industrial electric motors and controls. Ten of those years were with a leading software as a service (SAAS) public encryption company where he served as controller and CFO. Under Mike's leadership, the company drastically improved earnings and cash flow while reducing the company's risk profile and improving compliance. They achieved best in class public company audit committee ISS governance ratings. As a Vice President of Finance and Controller in the telecommunications and heavy industrial electric motors and controls industries, Mike managed large groups including director level direct reports in multi-locations, both domestic and international (US, Canada, UK, Germany, Italy and Israel). In addition to accounting and reporting responsibilities, a major part of his role included implementing and integrating enterprise wide software (SAP) across several manufacturing divisions. Over a career that spans auditing, controllership, financial systems and senior executive financial management, Mike's experience reaches across technical accounting, financial reporting and disclosure controls, risk avoidance, multi-location, SEC reporting, public company corporate governance, equity compensation, manufacturing cost accounting and includes HR and benefits, IT, facilities management and strategy. Mike earned a BA in English with a concentration in business from John Carroll University and an MS in Accountancy from DePaul University. He is a CPA and is a member of the Ohio Society of CPA's.

Thomas Bartlett – Chief Operating Officer

Tom Bartlett has over thirty years of private equity, investment banking, corporate advisory, and operating experience. Throughout his career, Tom has financed, advised or served in executive management capacities to drive growth and value appreciation of businesses operating across a spectrum of industries and business models. Prior to joining Alternate Health Corp. as its Chief Operating Officer, Tom served as the President and CFO of an insurance services company where Tom was directly responsible for executing multiple acquisitions and financings for the business in addition to overseeing the overall operational and financial functions of the company. In his capacity of COO at Alternate Health, Tom is primarily responsible for implementing and directing growth and diversification strategies across the AHC platform. Tom has a BBA in finance and management from Baylor University.

Jamison Feramisco – Director

Dr. Jamison Feramisco, MD, PhD, is trained in both Internal Medicine and Dermatology and completed his PhD research thesis in the laboratory of Nobel Laureates Drs. Mike Brown and Joe Goldstein at UT Southwestern Medical Center. He has an extensive history of success in founding, funding, and growing numerous healthcare service and technology companies. Dr. Feramisco is the founder and President of Apri Health (formerly Transfuse Solutions), a next-generation healthcare data analytics and change management company based in Dallas, Texas. He also serves as Chief Medical Officer of both Third Eye Health, a technology-enabled medical services company, and Advanced Healthcare Solutions nursing home chain. His former positions include founder and President of Golden Healthcare of Temecula, California, a medical service corporation specializing in home health care designed with the patient's need for personal care and safety in mind; Chief Medical Officer of Scanadu, a cutting edge wearable device company with headquarters at NASA's Moffitt Field, CA.; co-founder and chief medical officer/chief operating officer of Dermlink, one of the first consumer focused tele-dermatology software companies. He has served on the board of multiple healthcare and technology companies and is an active mentor at many of the Bay Area healthcare incubators. Clinically, Dr. Feramisco focuses primarily on three areas of medicine: 1) Hospitalist Medicine - general medical care of hospitalized patients including patient care, teaching, research and leadership related to hospital medicine; 2) Dermatology, the medical care of the skin and its diseases; and 3) Wound Care, the medical care in the prevention of wound complications and the promotion of wound healing. Dr. Feramisco has a successful track record as an entrepreneur and is a respected Angel Investor and consultant for venture capital and private equity.

Adam Desmond - Director

Adam Desmond began his career at the Chicago Mercantile Exchange in the financial quadrant. He then went on to Raymond James and Associates where he helped develop a high yield fixed income department. This experience gave him the groundwork to found ASG Securities in 1998. There, his vision was to focus exclusively on small/mid-cap banks and thrift markets. In 2004, ASG Securities transformed into FIG Partners LLC. As Founder and one of the Managing Principals, Adam and his team added a research division to expand the business from a sales and trading platform into a full service investment banking firm. This implementation resulted in full research on over 120 banks. Under his leadership, as co-head of Investment Banking, Adam assembled a team of principals at raised more than $2.5 billion in equity since 2007 and completed more than 95 whole bank transactions throughout the United States. Through the trading platform Fig was a market maker in over 800 community banks and thrifts. As Fig's reputation grew, Adam directed the strategy to create both Fixed Income and Corporate Development departments to implement cross selling to Fig's client base. With its headquarters in Atlanta, FIG Partners expanded from one office and a hand full of employees, to offices in Chicago, Los Angeles, San Francisco, Dallas, New Jersey and Charlotte, employing over 60 people. Adam's expertise in the banking sector has brought him into contact with top executives from over 250 banks and thrifts, as well as building close relationships with the foremost institutional equity managers. He also served as a board member for Goldwater Bank in Scottsdale Arizona. Adam recently created Needle Rock Capital to leverage his past expertise in the financial industry and his relationships. In addition, he founded Needle Rock Farms, to explore alternative health solutions. Adam prides himself on being a member of the Elks Club. He enjoys supporting and servicing many charitable organizations. For example, Adam sponsored charitable organizations in India and Laos. Through St. Mary's Catholic Church in Aspen, he helped fund the building of a school in the Philippines. Adam graduated from the University of Wisconsin – Madison with a Bachelor of Arts in International Economics and Political Science.

Marcelin O'Neill – Corporate Secretary and Compliance Officer

Marcelin O'Neill is currently a Director and CEO of Cervantes Capital Corp., and also presently the Compliance Officer and Corporate Secretary of Alternate Health Corp. Ms. O'Neill served as a Director of Jagercor Energy Corp. from December 2011 to May 2014, and as Chief Financial Officer and Corporate Secretary of Jagercor, from July 2013 to May 2014. She served as a director of Brandenburg Energy Corp. from February 2008 to February 2013, and as Chief Financial Officer and Corporate Secretary from August 2010 to February 2013. Ms. O'Neill served as the Vice President of Corporate Affairs of Mandalay Resources Corporation from April 2009 to March 2010, and from April 2007 until May 2008, she served as a director of Mandalay. Since 1994 Ms. O'Neill has worked with such companies as Augusta Resource Corporation, Westcoast Energy Inc., and the Lundin Group. In 1987, Ms. O'Neill graduated from the British Columbia Institute of Technology, where she studied Business Management, and has successfully completed the CSC and the CPH, both with honors. Ms. O'Neill is the managing director of Accrete Consulting Inc., a company which provides corporate governance and management services to public companies. With over 23 years of experience in public company management, Ms. O'Neill brings a varied scope of knowledge to the companies with which she works.

Resignations

The Company wishes to announce that the following individuals have tendered their resignations to the respective roles as indicated: Marjorie Sanderson resigned as Director and Chief Executive Officer, Jim Griffiths resigned as Chief Financial Officer, Marcelin O'Neill resigned as a Director of the Company; and Rick Macartney resigned as a Director of the Company. Alternate Health would like to thank Ms. Sanderson, Mr. Griffiths, Ms. O'Neill, and Mr. Macartney for their assistance while serving in the aforementioned roles.

The Board of Directors is now comprised of Bryan Korba, Jim Tykoliz, Jim Griffiths, Jamison Feramisco and Adam Desmond.

"This is the right time for Bryan and his incoming team to lead Alternate Health into the next chapter of our company's exciting future. Bryan brings a unique combination of entrepreneurial experiences with a dedication to creating and executing dynamic strategic plans. His vision, strategy and execution track record is exactly what Alternate Health needs at this point of rapid growth and market expansion. I am confident in the strong leadership that Bryan will bring to our company and know he will energize and inspire our employees, shareholders, customers and partners," said Alternate Health Director Jim Griffiths.

About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

"Bryan Korba"

Chairman and CEO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


SOURCE Alternate Health Corp.

To view this news release in HTML formatting, please use the following URL:

http://www.newswire.ca/en/releases/archive/February2017/10/c7695.html

%SEDAR: 00037135E

For further information: contact Bryan Korba at info@alternatehealth.ca

CO: Alternate Health Corp.

CNW 17:12e 10-FEB-17


ALTERNATE HEALTH CORP. ANNOUCES CONSULTING AGREEMENT

VANCOUVER, B.C. – January 31, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company") is pleased to announce that that it has entered into a consulting agreement with a consultant of the Company for the purposes of compliance and regulatory filings. Pursuant to the terms of the consulting agreement, the Company will issue 50,000 common shares to the consultant for past services rendered.


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


AMERICAN MEDICAL ASSOCIATION (AMA) APPROVES FIRST ONLINE VIDEO EDUCATIONAL PROGRAM FOR PRACTITIONERS ON CBD AND THE ENDOCANNABINOID SYSTEM

VANCOUVER, B.C. – January 30, 2017 - Alternate Health Corp. (CSE:AHG) (the "Company") is pleased to announce the first continuing medical education course on the "Endocannabinoid System and Cannabidiol." The course is accredited through the University of Louisville in accordance with the American Medical Association (AMA) and the American Board of Medical Specialties (ABMS) educational requirements, and provides a comprehensive overview of the endocannabinoid system (ECS), and the vital role it plays in various physiological functions of the human body.

"Doctors and medical professionals have been waiting for a proper medical education program to provide details for this emerging medicine," said Jim Griffiths, CFO for Alternate Health. This program is the culmination of many years of investigation and research, coupled with a substantial investment in production to create a quality and esthetically pleasing education program for Doctors and healthcare practitioners."

In order to demonstrate the quality and comprehensive nature of this program, Alternate Health have included a complimentary sample (https://youtu.be/uUl3kTg_6QQ) of the endocannabinoid course, and will commence sales of the online course on our website (www.alternatemedical.com) and at events across the United States and Canada.

The Company has formed a wholly-owned subsidiary called Alternate Medical Media, LLC ("AMM") and this course will be an important asset in creating the means for attracting and effectively communicating with the Company's targeted audience. AMM's services are distinctive in utilizing advanced media techniques to effectively communicate complex information and introduce new, innovative and emerging diagnostics, treatments and non-traditional solutions.

"This course, and the ones we currently have in development are a breakthrough in the digital medical education industry in that they combine the most current graphics and technology" said Rick Anderson, Managing Director for Alternate Medical Media. "I've been working in the CME [continuing medical education] space for many years and when I show our new course to my institutional contacts they are all truly amazed by what they see."

According to annual data from the ACCME, continuing medical education is currently a $2.6 billion industry. AMM will launch the endocannabinoid course this week, selling for $399 with practitioners receiving full credits for its completion.

The course will be available online at www.alternatemedical.com


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


Alternate Health Corp. Announces Cannabis Production Partnership with California Native American Band for Operation within Federal Law

VANCOUVER, B.C. – January 26, 2017 - Alternate Health Corp. (CSE:AHG)(the "Company") is furthering its announcement of entering into a 30 year joint venture agreement with the Alturas Native Band ("Alturas") to support the development, production, research and extraction of CBD's used to create medicinal products in this state-of-the-art cannabis production facility. The cannabis produced at this facility will be extracted on-site to create highly valuable cannabidiol for use in producing exclusive products that utilize Alternate Health's patented delivery systems.

Currently, Alturas is operating a 25,000 square foot indoor cannabis grow facility and the joint venture will use its production to develop cannabis related medicine for testing and ultimately selling in California and potentially worldwide.

On December 11, 2014, the US Justice Department held over that Native Americans can grow and sell cannabis on Native reserve lands in accordance with state laws. The joint venture plans to operate a state compliant production, extraction and manufacturing facility using its patented delivery system for CBD related medicine in the state of California.

"We are extremely excited to partner with the Alturas Band," said Jim Griffiths, CFO for Alternate Health. "We will bring our expertise in extractions and medicinal products to create a strong, stable and federally legal cannabis production operation in the state of California. We believe this relationship strongly positions Alternate Health for success in the this market."

The facility, a 12 acre compound, will allow Alternate Health to manufacture substantial volume of sublingual, dissolvable pills and patches that can then be distributed to the many state compliant collectives and medical entities.

Alternate Health expects to close the joint venture transaction in early February, 2017 and commence business in the spring of 2017. Alternate Health will receive 45% of the proceeds and the Alturas Native Band will receive 55% (In accordance with typical sovereign rights contracts).


About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

Director of New Ventures

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


Alternate Health Corp. Provides Update on CBD Patented Delivery Systems and First Day of Trading

VANCOUVER, B.C. – January 25, 2017 - Alternate Health Corp. (CSE:AHG)(the "Company") wishes to expand on its previously announced transdermal patch and non-pharmaceutical sublingual dissolvable tablet delivery systems being licensed under its Medipatch and Sentar agreements. These patented delivery systems represent a safe and controlled method for delivering measured doses of pharmaceutical grade CBD and THC based medicines. The Medipatch and Sentar Agreements are expected to close in the next two weeks.

While terms of the Agreements provide for long-term product development and commercialization, the immediate opportunity to manufacture and distribute proprietary products in the US, Canada and the United Kingdom represent significant revenue generating businesses for Alternate Health for many years to come."These patents allow Alternate Health to specifically control dosages and provide a safe, medically viable delivery system for cannabis and CBD's," said Jim Griffiths, CFO for Alternate Health. "This furthers the Company's plans to become an international leader in cannabis derived medicines."

Under the previously announced pending Alturas Joint Venture Agreement, an existing building on sovereign Native American land in northern California will be used as a research and testing facility. It will also include a CBD extraction and refinement plant expected to be operational this spring. Alternate Health is also currently in discussions with several Canadian LP's (licensed providers) for manufacturing and delivering its patented products and delivery systems in the Canadian market.

According to USA Today, the California marijuana Industry is estimated to grow to $25 billion annually, and is set to eclipse $50 billion by 2026. "Alternate Health is uniquely positioned for licensing their manufacturing pharmaceutical grade delivery systems of CBD and THC healing products in this fast-growing new marketplace," said Jim Tykoliz, Director of New Ventures, Alternate Health. "It is Alternate Health's intentions to provide organic, safe and healthy medicines through our patented delivery systems to patients around the world, and the California market represents a significant starting point for us."


Successful First Day of Trading

On January 24th, 2017, the Company's first day of trading on the Canadian Securities Exchange, Alternate Health's shares opened at $3.28, traded at a high of $3.50, at a low of $3:15, and closed at $3.28; on volume of 44,300 shares.

Consulting Agreement

About Alternate Health Corp.

Alternate Health (http://www.alternatehealth.ca) is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward- looking statements.


ALTERNATE HEALTH CORP. ANNOUNCES PRIVATE PLACEMENT OFFERING

VANCOUVER, B.C. – January 24, 2017 – Alternate Health Corp. (the "Company" or AHC) announces that the Company will complete a non-brokered private placement of up to 3,000,000 common shares at a price of $3.25 per common share for aggregate gross proceeds of up to $9,750,000. The Company may pay finder's fees as permitted by applicable securities laws and the policies of the CSE.


Joint Venture Agreement with Alturas Indian Rancheria

The Company is also pleased to announce that it has entered into an agreement with Alturas Indian Rancheria ("Alturas") to form a Joint Venture Company where ownership in the venture will be 55% Alturas and 45% AHC. The Agreement provides that Alturas and AHC, or its subsidiary, enter into a 30 year land lease (including all buildings) on a 10 acre site, owned by Alturus. A new CBD Testing and Research Facility is intended to be constructed on this land, with a focus on furthering research and development in the use of Cannabidiol for medical and therapeutic treatments. California is the world's largest medical marijuana market and will soon open the market for recreational sales this year, with this Agreement expected to strongly position AHC to become a market leader.

AHC will issue 1,500,000 common shares to Alturas upon closing of the transaction, with a potential additional 1,500,000 common shares of the Company to be issued at a future date, for the expansion of the business, subject to approvals by both parties. The Agreement further provides that AHC annually grant warrants to Alturus, to purchase 100,000 common shares of the Company, for each year the Joint Venture is in operation, which is estimated to be 30 years. Each warrant grant will expire one year from the date of the grant, and the warrant exercise price will be set in accordance with the Canadian Securities Exchange polices and securities regulations.

Consulting Agreement

The Company is pleased to announce that it has entered into a consulting agreement with a US-based consultant effective January 23, 2017 for the purposes of delivering hospital relationships for the Company's business objectives. Pursuant to the terms of the consulting agreement, the Company will issue 250,000 common shares, which will be subject to escrow. The release of the escrowed shares will be subject to certain performance conditions.

About Alternate Health Corp.

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs.

Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.

On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths Director and CFO

For further information, contact Jim Griffiths at 416-607-5757.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. There are no assurances that the agreements and transactions described in this news release will close.


ALTERNATE HEALTH CORP. ANNOUNCES PRIVATE PLACEMENT OFFERING

VANCOUVER, B.C. – January 20, 2017 – Alternate Health Corp. (the "Company" or AHC) announces that the Company will complete a non-brokered private placement of up to 3,000,000 common shares at a price of $3.25 per common share for aggregate gross proceeds of up to $9,750,000. The Company may pay finder's fees as permitted by applicable securities laws and the policies of the CSE.

The Company intends to use the proceeds of the private placement for commercialization of its recently acquired CBD delivery system licenses, expansion of its toxicology laboratory business acquired in January and for targeted revenue generating acquisitions in the health care industry.

The Company's common shares are listed on the CSE under the symbol "AHG" and trading will commence on January 24, 2017.


On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

For further information, contact Jim Griffiths at 416-607-5757.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms.

Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. There are no assurances that the financing described in this news release will close or will close for the amount announced.


ALTERNATE HEALTH CORP. RAISES $4.37 MILLION IN PRIVATE PLACEMENT AND ANNOUNCES CSE LISTING

VANCOUVER, B.C. – January 19, 2017 – Alternate Health Corp. (the "Company" or AHC) is pleased to announce that the Company has received subscription agreements totaling gross proceeds of $4,371,530.50 following closing-off sales of its current private placement offering at $1.50 per common share. The offering was over-subscribed by $371,530.50, for the total issuance of 2,914,354 common shares. Formal closing of the private placement will occur tomorrow. Finder's fees of $378,720.15 will be paid to Mackie Research Capital Corporation as permitted by CSE policies and applicable securities laws. All common shares issuable under the private placement will have a four month hold period in accordance with securities laws.

AHC is pleased to announce that today, the Canadian Securities Exchange issued its Bulletin announcing the Company's listing on the CSE, with trading commencing on January 24, 2017 under the symbol "AHG". Please refer to the link below to access the CSE Bulletin. CLICK HERE TO READ BULLETIN

Agreement to acquire 20% of Clover Trail Capital LLC

Clover Trail Capital LLC, ("Clover") a Texas-based limited liability company, owns approximately 40% of Sun Clinical Laboratories LLC, which refers toxicology samples to AHC subsidiary Alternate Health Labs Inc. including samples directed by Paradigm Health Solutions LLC. The arm's length acquisition price of US $5,500,000 was based on Clover's past and forecasted revenues and will be settled with 4,557,150 AHC common shares at an agreed price of $1.00 per share and an 18 month term note for US $1,993,750 payable to the seller. The transaction is expected to close in early February. Clover is indirectly controlled by Dr. Michael Murphy who recently completed a Lab Development Agreement with AHC.

10-year renewable license agreement with EFT Global Holdings

EFT Global Holdings / Sentar Pharmaceuticals has agreed to grant AHC 10 year worldwide license rights to its patented Sublingual Delivery Systems to administer CBD and THC nutraceuticals in tablet form ("Technology"). Consideration for the license is 850,000 AHC common shares at an agreed price of $1.00 plus a royalty on future sales or profits.

In addition, the Company agreed to pay consulting fees in the form of 2,118,500 AHC common shares at an agreed price of $1.00 per share for services rendered for assistance in obtaining the license, the ongoing development and commercialization of the Technology and assistance in obtaining regulatory approvals and permits for related products. All parties to the license and consulting agreements are arm's length. These transactions are expected to close in February.

Agreement to purchase transdermal medical patch technology

AHC has agreed to acquire from Dr. James Williams ("Williams") provisional patent #2016-0361271-A1, proprietary transdermal patch technologies, and certain assets owned by Medipatch Inc, a company controlled by Williams. When applied to the skin, the transdermal patch is capable of transferring active pharmaceutical or nutraceutical ingredients via the skin and into the body.

Under the agreement, Williams will receive 150,000 AHC common shares, 50,000 on closing and 100,000 when the technology and certain assets are transferred to AHC. The agreement also provides that Williams be granted warrants to acquire 25,000 AHC common shares at a purchase price of $3.35 per common share for a period of 18 months from closing which is expected to occur on or before February 8, 2017. On closing Williams or an affiliate will sign a management agreement with AHC to operate the commercial business using the technology and the acquired assets that will compensate Williams with a monthly retainer and a royalty from sales or profits generated from the Medipatch assets and intellectual Property acquired from Williams.

Agreements for further consulting services

The Company has also signed consulting services agreements with five individuals, for cash, shares and warrants including aggregate share compensation of 562,650 AHC common shares and 180,000 warrants to acquire AHC common shares at $1.00 per share for an 18-month period ending July 8, 2018. The consulting services include: Ongoing research, product development and manufacturing support related to newly licensed technologies, general management services for the Company's Continuing Medical Education Business, legal services, consulting related to sourcing new customers for the Company and business acquisition opportunities.


For further information, contact Jim Griffiths at 416-607-5757. On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms.

Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements. There are no assurances that the agreements and transactions described in this news release will close.


ALTERNATE HEALTH CORP. CLOSES THREE KEY AGREEMENTS PRIOR TO CSE LISTING

VANCOUVER, B.C. – January 13, 2017 – Alternate Health Corp. (the "Company" or AHC) is pleased to announce the finalization of three key agreements to strengthen the Company's position in the medical education and laboratory testing market.

These agreements further AHC's goal of improving patient care and outcomes by acquiring assets and exclusive rights to new research and technologies. The details for each agreement are listed below.


Acquisition of Alternate Health Labs Inc.

AHC has closed the Lab Development Agreement with Dr. Michael Murphy ("Murphy") with the acquisition of Alternate Health Labs Inc. ("AHL") for consideration of 1,920,000 common shares of AHC at the previously agreed price of $1.00 per share.

AHL operates a 17,000 sq ft toxicology laboratory in San Antonio, Texas, with current testing equipment capacity to process up to 70,000 urine and blood samples per month and sufficient space to double its processing capacity. LMK Management LLC, a company controlled by Murphy, will continue to manage AHL's toxicology laboratory business.


Cooperation and Consulting Agreement with Paradigm Health Solutions

AHC and Paradigm Health Solutions LLC ("Paradigm") have agreed on a mutual cooperation and consulting agreement with the issue of 1,500,000 common shares of AHC at the previously agreed price of $1.00 per share. Paradigm is an aggregator of toxicology samples and under the Consulting Agreement it has agreed to direct all of its toxicology and blood samples to AHL via Sun Clinical Laboratories LLC, an entity indirectly controlled by Murphy.

AHC shares are being held in escrow and will be released in tranches as Paradigm achieves agreed sample delivery targets of up to 150,000 samples per month and/or signs four hospital contracts for the benefit of Paradigm and AHL.


Exclusive Rights to Medical Cannabis Education, Patents and Research

AHC is issuing 350,000 AHC common shares to Dr. Michelle Reillo as partial consideration for granting AHC and its subsidiaries the exclusive rights to commercialize her American Medical Association approved continuing medical education course on the use of medical Cannabis as well as rights to certain patents and ongoing research related to medical cannabis.


Private Placement and CSE Listing

The Company has filed its CSE Form 2A Listing Statement dated January 12, 2017 and the Listing Statement contains additional details of the key agreements described above. The Company expects that its previously announced $4 million private placement will be fully subscribed and will close coincident with the CSE Listing Bulletin expected next week./p>

For further information, contact Jim Griffiths at 416-607-5757. On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health Corp. is a leader in software applications and processing systems for the medical industry using proprietary technology platforms.

Through its subsidiaries, Alternate Health Corp. offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health Corp.'s goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ALTERNATE HEALTH CORP. RECEIVES RECEIPT FOR PROSPECTUS AND CONDITIONAL APPROVAL TO LIST SHARES ON CSE

Vancouver, BC, December 23, 2016 – Alternate Health Corp. (the "Company" or "AHC") is pleased to announce that it has filed and obtained a receipt from the Ontario Securities Commission dated December 5, 2016 for its Final Non-Offering Prospectus ("Prospectus") dated November 29, 2016. A copy of the Prospectus is available on SEDAR under the Company's profile at www.sedar.com.

The Company has also received conditional approval from the Canadian Securities Exchange (the "CSE") for the listing of its common shares on the CSE subject to the completion of customary requirements of the CSE, including the receipt of all required documentation. Once final approval is received, the common shares of AHC will commence trading under the trading symbol: AHG.

The Company announces that it has completed a share exchange (the "SEA") with the securityholders of Alternate Health Inc. ("AHI"). A total of 32,519,636 common shares were issued to former AHI shareholders under the SEA and 606,250 replacement warrants. The replacement warrants all have an exercise price of $1.50 and expire in March, September, and October 2017, respectively. AHI is now a wholly-owned subsidiary of the Company and the business of AHI is the Company's principal focus. Following the closing of the SEA, the Company has 32,916,236 outstanding common shares.

The Company also wishes to announce a private placement for gross proceeds up to $4,000,000. The Company will issue up to 2,666,667 common shares at a price of $1.50 per common share. All common shares issued under the private placement will be subject to a 4 month hold period. The Company may pay finder's fees in accordance with applicable securities laws.

For further information, contact Jim Griffiths at 416-607-5757.


On behalf of the Board of Directors of

ALTERNATE HEALTH CORP.

Jim Griffiths

CFO and Director, Alternate Health Corp.

About Alternate Health

Alternate Health is a diversified healthcare company that uses its expertise in technology to revolutionize patient care and service delivery in both traditional and complementary medical fields. With investments in research, education and cutting edge technology, Alternate Health is a leader in software applications and processing systems for the medical industry using proprietary technology platforms. Through its subsidiaries, Alternate Health offers services ranging from medical practice and controlled substance management software to blood analysis and toxicology labs, to clinical research and continuing education programs. Alternate Health's goal is to continue to lead the medical industry with data-driven results in patient care and product development.


Neither the CSE nor its Regulation Services Provider (as that term is defined in the policies of the CSE) accepts responsibility for the adequacy or accuracy of this release.

Statements included in this announcement, including statements concerning our plans, intentions and expectations, which are not historical in nature are intended to be, and are hereby identified as "forward-looking statements". Forward-looking statements may be identified by words including "anticipates", "believes", "intends", "estimates", "expects" and similar expressions. The Company cautions readers that forward-looking statements, including without limitation those relating to the Company's future operations, business prospects and financing plans, are subject to certain risks and uncertainties that could cause actual results to differ materially from those indicated in the forward looking statements.


ANNUAL GENERAL MEETING

Vancouver, BC, May 27, 2016 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate" or the "Company"). wishes to announce that all of the resolutions put forth at the Company's Annual General Meeting of Shareholders held on May 26, 2016 have been approved.

In addition to the standard annual shareholder resolutions which include setting the number of directors, the election of the directors of the Company, and the appointment Scarrow Yurman & Co., Chartered Professional Accountants, as auditors for the coming year, the Company's shareholders approved and ratified the Company's 15% rolling stock option plan. A majority of votes cast, by disinterested shareholders, was received on this resolution.

At the meeting the following directors were elected; and directly after the meeting the Board of Directors appointed the following Officers:

Directors:
Bobby Curtola
James Tykoliz
Rick Macartney
Marcelin O'Neill
Marjorie Sanderson
Jim Griffiths

Officers:
Bobby Curtola, Chairman
Marjorie Sanderson, Chief Executive Officer
Jim Griffiths, Chief Financial Officer
Marcelin O'Neill, Corporate Secretary

About Alternate

Alternate is a reporting issuer, duly incorporated in the Province of British Columbia, currently seeking a listing on the Canadian Securities Exchange.

For further information on Alternate, please contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com


ALTERNATE HEALTH CORP. AGREES TO COMPLETE SHARE EXCHANGE WITH ALTERNATE HEALTH INC.

Vancouver, British Columbia –November 27, 2015 – Alternate Health Corp. (the "Company" or "AHC") is pleased to announce that it has agreed to the terms of a share exchange agreement (the "Share Exchange Agreement") with Alternate Health Inc. ("AHI") to complete the proposed acquisition of AHI.

AHI is a privately held, Ontario company formed as a medical services company in the Canadian market with interest in promoting both traditional (i.e. physicians) and non-traditional (i.e. chiropractors, Naturopaths) solutions to modern healthcare. AHI has one wholly-owned subsidiary, CanaCard Inc., also an Ontario company. AHI holds exclusive licenses in Canada for the VIP-Patient Electronic Medical Records platform and the CanaCard Controlled Substances Patient Management System.

The transaction will be carried out as a share exchange (the "Share Exchange") pursuant to which, among other things: (i) AHC will acquire all of the issued and outstanding shares of AHI, and AHI will become a wholly-owned subsidiary of AHC; (ii) shareholders of AHI will be issued one common share of AHC for every one common share of AHI held at the effective time of the Share Exchange; and (iii) warrant holders of AHI will be issued warrants of AHC on equivalent terms as, and in replacement of, all outstanding AHI warrants, and the AHI warrants will be cancelled.

Completion of the Share Exchange remains subject to a number of conditions, including but not limited to, satisfaction of standard closing conditions for transactions of this nature. The Company intends to apply for listing on the Canadian Securities Exchange as part of completion of the Share Exchange.

ON BEHALF OF THE BOARD

"Bobby Curtola"

Director and Chairman

For further information contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com

This news release is not an offer of securities of the Company for sale in the United States. The above described issuances of securities of the Company have not been and will not be registered under the U.S. Securities Act of 1933, as amended, and may not be offered or sold in the United States absent registration or an applicable exemption from registration. This news release shall not constitute an offer to sell or solicitation of an offer to buy nor shall there by any sale of the above described securities in any jurisdiction in which such offer, solicitation or sale would be unlawful.

Disclaimer for Forward-Looking Information:

This news release contains "forward-looking information" within the meaning of applicable securities laws relating to the proposal by the Company to complete the Share Exchange, issuances of securities thereunder and associated transactions, including statements regarding the terms and conditions of the Share Exchange Agreement and AC/3680132.1 statements regarding AHI's business, products and future plans. Although the Company believes that the expectations reflected in the forward looking information are reasonable, there can be no assurance that such expectations will prove to be correct. Readers are cautioned to not place undue reliance on forward-looking information. Such forward looking statements are subject to risks and uncertainties that may cause actual results, performance and developments to differ materially from those contemplated by these statements depending on, among other things, the risks that the parties will not complete the Share Exchange and associated transactions for any reason, that the ultimate terms of the Share Exchange and associated transactions will differ from those that currently are contemplated, and that AHI's products and plan will vary from those stated in this news release and that AHI may not be able to carry out its business plans as expected. Except as required by law, the Company expressly disclaims any obligation, and does not intend, to update any forward looking statements or forward-looking information in this news release. The statements in this press release are made as of the date of this release.

AC/3680132.1


ALTERNATE HEALTH CORP. APPOINTS DIRECTOR AND CHIEF FINANCIAL OFFICER

Vancouver, BC, September 8, 2015 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate" or the "Company"). Alternate is pleased to announce the appointment of Jim Griffiths as Chief Financial Officer, and to the Company's Board of Directors.

Mr. Jim Griffiths is a current member of the Board of Trustees of the Center for Addiction and Mental Health ("CAMH") in Toronto, Jim has a Masters in Business Administration, is a chartered accountant, and has over 30 years of experience in the real estate development/financing industries. He was the Vice President Finance of Genstar Property Corporation and the President of First City Development Corp. He was also President and director of RealFund, Canada's first public Real Estate Investment Trust and Krystal Bond Inc. During his career, he has had responsibility for real estate asset acquisitions and sales of over $2 billion. In addition he is very experienced in financing real estate and has negotiated and placed real estate loans in an amount exceeding $2.5 billion.

Jim was a past director of Pinetree Capital Inc., the Canadian Institute of Public Real Estate Companies and was the Founding Chairman of the Association of Foreign Investors in U.S. Real Estate. He is currently a director of Allied Properties Real Estate Investment Trust, Enssolutions Group Inc., and Champion Partners and is President of KLC Capital Investment Corporation, which provides financial advisory services.

About Alternate

Alternate is a reporting issuer, duly incorporated in the Province of British Columbia, currently seeking a listing on the Canadian Securities Exchange.

For further information on Alternate, please contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com


ALTERNATE HEALTH CORP. APPOINTS BOARD OF DIRECTORS AND OFFICERS OF THE COMPANY

Vancouver, BC, May 29, 2015 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate" or the "Company"). Alternate is pleased to announce recent appointments to the Company's Board of Directors and its Officers.

Bobby Curtola – Director and Chairman

As an icon of the Canadian Music Industry, Bobby Curtola ranks among the most decorated artists of all time, with 25 gold records and many year of touring internationally. Mr. Curtola is also involved in many North American charities and has hosted numerous telethons coast to coast in Canada every year including charitable work in Indonesia, Bulgaria, Ecuador and the USA. In 1998, Mr. Curtola was made a Certified Member of the Order of Canada in recognition of his long service to the Canadian Music Industry as well as his humanitarian work around the world.

Marjorie Sanderson – Director and Chief Executive Officer

Ms. Sanderson graduated from the Hospital for Sick Children as a Registered Nurse, and was team leader in 1970 with a specialty in the treatment of burns in children with learning disabilities. Ms. Sanderson worked in the medical sector as a registered nurse until 1997. Since 1976, Ms. Sanderson has worked as a Canadian Tax Consultant working with trusts, corporate and personal taxes; and is owner of the accounting firm, Partners Income Tax Services, a wholly owned division of Templus Inc. Ms. Sanderson taught stress management at the University of Toronto, and from 1972 to 1984, also taught tax accounting for the CGA. Since 2011 Ms. Sanderson has served as a member of the Women's International Leadership Association.

Rick Macartney - Director

Rick Macartney has over 25 years in both senior management and consulting roles, assisting a wide variety of businesses to profitability, develop strategic and financial plans, re-organize and streamline operations, and develop new businesses. With both Bachelor's and Master's degrees in Economics, Mr. Macartney has accomplished many assignments in a wide variety of both large and small businesses. For the past nine years he has consulted with private clients in markets as diverse as entertainment, real estate, solar energy, and other sectors.

James E. Tykoliz – Director

Building on his degrees in Finance & Economics from the University of Western Ontario, Mr. Tykoliz managed large accounts for pharmaceutical and packed goods companies for A.C. Nielsen Market Research before becoming an entrepreneur and building and managing dot.com operations. Mr. Tykoliz brings Alternate Health over 27 years of sales solutions and client oriented service experience in data driven, financial service environments.

Marcelin O'Neill – Director and Corporate Secretary

Ms. O'Neill served as a director of Jagercor Energy Corp. from December 2011 to May 2014, and as Chief Financial Officer and Corporate Secretary of Jagercor, from July 2013 to May 2014. She served as a director of Brandenburg Energy Corp. from February 2008 to February 2013. Ms. O'Neill was appointed as the Vice President of Corporate Affairs of Mandalay Resources Corporation from April 2009 to March 2010, and from April 2007 until May 2008, she served as a director of Mandalay. Since 1994 Ms. O'Neill has worked with such companies as Augusta Resource Corporation, Westcoast Energy Inc., and the Lundin Group. In 1987, Ms. O'Neill graduated from the British Columbia Institute of Technology, where she studied Business Management, and has successfully completed the CSC and the CPH, both with honours. Ms. O'Neill is the managing director of Accrete Consulting Inc., a company which provides corporate governance and management services to public companies. With over 21 years of experience in public company management, Ms. O'Neill brings a varied scope of knowledge to the companies with which she works.

About Alternate

Alternate is a reporting issuer, duly incorporated in the Province of British Columbia, currently seeking a listing on the Canadian Securities Exchange.

For further information on Alternate, please contact:

Alternate Health Corp.
Bobby Curtola
Director & Chairman
Telephone: +1.902.809.4243
Email: b.curtola@gmail.com


ALTERNATE HEALTH CORP. (FORMERLY 1017344 B.C. LTD.) COMPLETES A PLAN OF ARRANGEMENT WITH RISKE CAPITAL CORP.

Vancouver, BC, April 24, 2015 – Alternate Health Corp. (formerly 1017344 B.C. LTD.) ("Alternate"). Alternate is pleased to announce that it has completed a statutory arrangement under a Plan of Arrangement (the "Arrangement") among Alternate and Riske Capital Corp. ("Riske"). As a result of completing the Arrangement, Alternate became a reporting issuer in Alberta and British Columbia.

On October 29, 2014, Riske and Alternate, entered into an Arrangement Agreement and Plan of Arrangement (the "Arrangement Agreement").

Completion of the Arrangement as set forth in the Arrangement Agreement was approved by the shareholders of Riske and 1017344 B.C. LTD. on December 1, 2014; and a final order granted by the Supreme Court of British Columbia on December 3, 2014 in accordance with Part 9 of the Business Corporations Act (British Columbia).

By approval of the Board of Directors of Riske, upon the Arrangement becoming effective on April 15, 2015, Alternate became a reporting issuer in the jurisdictions of Alberta and British Columbia. The CUSIP for the Common Shares of Alternate is 02090B102.

Alternate was incorporated on October 26, 2014 and its fiscal year end is December 31. 1017344 B.C. Ltd. changed its name to "Alternate Health Corp." on April 16, 2015.

About Riske:

Riske is a business development services company. It provides business development services to new and emerging businesses, including making introductions to accountants, lawyers, brokers, transfer agents, and various other professionals and service providers to assist companies in raising capital and going public. It also advises companies on corporate structure and in business development, including seeking and advising on opportunities in mergers and acquisitions. It intends to take our compensation through a combination of securities and monetary fees.

For further information on Alternate, please contact:
Alternate Health Corp.
Howard Mann
Chief Executive Officer
Telephone: 1.310.926.2141
Email: hmann@dcnetcast.com

For further information on Riske, please contact:
Riske Capital Corp.
Dustin Riske
Chief Executive Officer
Telephone: 604.724.6362
Email: dustin@bullandbearwealth.com

Disclaimer for Forward‐Looking Information. Statements in this press release regarding Riske and Alternate which are not historical facts are "forward‐looking statements" that involve risks and uncertainties. Such information can generally be identified by the use of forward‐looking wording such as "may", "will", "expect", "estimate", "anticipate", "intend", "believe" and "continue" or the negative thereof or similar variations. Since forward-looking statements address future events and conditions, by their very nature they involve inherent risks and uncertainties. Actual results could differ materially from those currently anticipated in such statements due to many factors. Except as required by law, Riske and Alternate do not intend to update any changes to such statements. Although management of each company believes that the expectations represented in such forward‐looking statements are reasonable, there can be no assurance that such expectations will prove to be correct. This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such.